The most commonly used polyspecific antihuman globulin reagent contains antibodies to which of the following?

The most commonly used polyspecific antihuman globulin reagent contains antibodies to which of the following?

• A. anti-IgG and anti-C3d
• B. anti-IgG and anti-C3b
• C. anti-IgM and anti-C4d
• D. anti-IgG and anti-C3c

Answer: (C)

The main idea is that a polyspecific antihuman globulin (AHG) reagent is designed to reveal two kinds of immune activity on red cells: IgG antibodies coating the cells and complement components that have been deposited on them. The IgG-targeting part of the reagent binds to IgG antibodies that have attached to red cell antigens, signaling that an IgG immune response is present. The complement-targeting part binds to C3 fragments (specifically C3d) that remain on the cell surface after complement activation. Detecting both signals increases sensitivity for clinically significant antibodies that could cause transfusion reactions or hemolytic disease of the newborn. That’s why anti-IgG together with anti-C3d is the best match. Anti-IgG detects the antibody coating, while anti-C3d detects complement activation on the red cell surface, which often accompanies clinically important antibodies. Other combinations, like anti-IgM with anti-C4d or anti-C3b or anti-C3c, aren’t used in the standard polyspecific AHG reagent for routine transfusion testing because IgM detection on red cells is less relevant under these conditions and C4d or the other C3 fragments are not the typical markers relied upon in this assay.

The main idea is that a polyspecific antihuman globulin (AHG) reagent is designed to reveal two kinds of immune activity on red cells: IgG antibodies coating the cells and complement components that have been deposited on them. The IgG-targeting part of the reagent binds to IgG antibodies that have attached to red cell antigens, signaling that an IgG immune response is present. The complement-targeting part binds to C3 fragments (specifically C3d) that remain on the cell surface after complement activation. Detecting both signals increases sensitivity for clinically significant antibodies that could cause transfusion reactions or hemolytic disease of the newborn.

That’s why anti-IgG together with anti-C3d is the best match. Anti-IgG detects the antibody coating, while anti-C3d detects complement activation on the red cell surface, which often accompanies clinically important antibodies. Other combinations, like anti-IgM with anti-C4d or anti-C3b or anti-C3c, aren’t used in the standard polyspecific AHG reagent for routine transfusion testing because IgM detection on red cells is less relevant under these conditions and C4d or the other C3 fragments are not the typical markers relied upon in this assay.